Deletion of CFTR translation start site reveals functional isoforms of the protein in CF patients

Cellular Physiology and Biochemistry

Volumn 24, Issue 5-6, 2009, Pages 335-346

  Ramalho, Anabela S ^a,b   Lewandowska, Marzena A ^c   Farinha, Carlos M ^a,b   Mendes, Filipa ^a,b,f   Gonçalves, Juan ^d   Barreto, Celeste ^e   Harris, Ann ^c   Amaral, Margarida D ^a,b  

^a UNIVERSITY OF LISBON   (Portugal)

^b NATIONAL INSTITUTE OF HEALTH DR RICARDO JORGE   (Portugal)

^c NORTHWESTERN UNIVERSITY   (United States)

^d HOSPITAL DO DIVINO ESPÍRITO SANTO   (Portugal)

^e HOSPITAL DE SANTA MARIA   (Portugal)

^f INSTITUTO TECNOLÓGICO E NUCLEAR   (Portugal)

Author keywords

Alternative translation; CFTR; Cystic Fibrosis; Mutation; N terminus; Truncated proteins

Indexed keywords

ISOPROTEIN; METHIONINE; TRANSMEMBRANE CONDUCTANCE REGULATOR;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; CAUCASIAN; CELL MEMBRANE TRANSPORT; CFTR GENE; CODON; CONTROLLED STUDY; CYSTIC FIBROSIS; EXON; GENE; GENE DELETION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PORTUGAL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN METABOLISM; PROTEIN PROCESSING; PROTEIN STABILITY; RNA ANALYSIS; TRANSLATION INITIATION;

EID: 70450231758     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000257426     Document Type: Article

References (41)

1. Collins FS: Cystic fibrosis: molecular biology and therapeutic implications. Science 1992;256:774-779.
2. Gadsby DC, Vergani P, Csanady L: The ABC protein turned chloride channel whose failure causes cystic fibrosis. Nature 2006;440:477-483.
3. Riordan JR: CFTR function and prospects for therapy. Annu Rev Biochem 2008;77:701-726
4. The CFTR mutation database: International Consortium for the Genetic Analysis of CF. http:// www.genet.sickkids.on.ca/cftr/. 2009.
5. Amaral MD: Processing of CFTR: Traversing the cellular maze-How much CFTR needs to go through to avoid cystic fibrosis? Pediatr Pulmonol 2005;39:479-491
6. WHO CF report: The molecular Genetic Epidemiology of Cystic Fibrosis. 2004.
7. Carroll TP, Morales MM, Fulmer SB, Allen SS, Flotte TR, Cutting GR, Guggino WB: Alternate translation initiation codons can create functional forms of cystic fibrosis transmembrane conductance regulator. J Biol Chem 1995;270:11941-11946
8. http://central.igc.gulbenkian.pt/cftr/vr/f/ramalho-sequence-cftr-exons- clones-pac-library-rpcip704.pdf 2009
9. Ramalho AS, Beck S, Farinha CM, Clarke LA, Heda GD, Steiner B, Sanz J, Gallati S, Amaral MD, Harris A, Tzetis M: Methods for RNA extraction, cDNA preparation and analysis of CFTR transcripts. J Cyst Fibros 2004;3(S2):11-15.
10. Ramalho AS, Beck S, Meyer M, Penque D, Cutting GR, Amaral MD: Five percent of normal cystic fibrosis transmembrane conductance regulator mRNA ameliorates the severity of pulmonary disease in cystic fibrosis. Am J Respir Cell Mol Biol 2002;27:619-627
11. AUG evaluator-http://l25.itba.mi.cnr.it/~webgene/wwwaug.html, Open Reading Frame Finder -http://www.ncbi.nlm.nih.gov/gorf/gorf.html. 2009.
12. Palmiter RD, Behringer RR, Quaife CJ, Maxwell F, Maxwell IH, Brinster RL: Cell lineage ablation in transgenic mice by cell-specific expression of a toxin gene. Cell 1987;50:435-443.
13. Tabcharani JA, Chang XB, Riordan JR, Hanrahan JW: Phosphorylation- regulated Cl-channel in CHO cells stably expressing the cystic fibrosis gene. Nature 1991;352:628-631.
14. Pissarra LS, Farinha CM, Xu Z, Schmidt A, Thibodeau PH, Cai Z, Thomas PJ, Sheppard DN, Amaral MD: Solubilizing mutations used to crystallize one CFTR domain attenuate the trafficking and channel defects caused by the major cystic fibrosis mutation. Chem Biol 2008;15:62-69.
15. Roxo-Rosa M, Xu Z, Schmidt A, Neto M, Cai Z, Soares CM, Sheppard DN, Amaral MD: Revertant mutants G550E and 4RK rescue cystic fibrosis mutants in the first nucleotide-binding domain of CFTR by different mechanisms. Proc Natl Acad Sci U S A 2006;103:17891-17896.
16. Farinha C, Penque D, Roxo Rosa M, Lukacs GL, Dormer R, McPherson M, Pereira M, Bot AGM, Jorna H, Willemsen R, DeJonge R, Heda GD, Marino CR, Fanen P, Hinzpeter A, Lipecka J, Fritsch J, Gentzsch M, Jensen T, Aleksandrov A, Aleksandrov L, Riordan JR, Mengos A, Rhim AD, Stoykova LI, Trindade AJ, Glick MC, Scanlin T, Ollero M, Edelman A, Amaral MD: Biochemical methods to assess CFTR expression and membrane localization. J Cyst Fibros 2004;3(S2): 73-77.
17. Farinha CM, Nogueira P, Mendes F, Penque D, Amaral MD: The human DnaJ homologue (Hdj)-1/heat-shock protein (Hsp) 40 co-chaperone is required for the in vivo stabilization of the cystic fibrosis transmembrane conductance regulator by Hsp70. Biochem J 2002;366:797-806.
18. Mendes F, Doucet L, Hinzpeter A, Ferec C, Lipecka J, Fritsch J, Edelman A, Jorna H, Willemsen R, Bot AG, de Jonge HR, Hinnrasky J, Castillon N, Taouil K, Puchelle E, Penque D, Amaral MD: Immunohistochemistry of CFTR in native tissues and primary epithelial cell cultures. J Cyst Fibros 2004;3(S2):37-41.
19. Schmidt A, Hughes LK, Cai Z, Mendes F, Li H, Sheppard DN, Amaral MD: Prolonged treatment of cells with genistein modulates the expression and function of the cystic fibrosis transmembrane conductance regulator. Br J Pharmacol 2008;153:1311-1323.
20. Rosenstein BJ, Cutting GR. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr 1998;132:589-595.
21. Hirtz S, Gonska T, Seydewitz HH, Thomas J, Greiner P, Kuehr J, Brandis M, Eichler I, Rocha H, Lopes AI, Barreto C, Ramalho A, Amaral MD, Kunzelmann K, Mall M: CFTR Cl-channel function in native human colon correlates with the genotype and phenotype in cystic fibrosis. Gastroenterology 2004;127:1085-1095.
22. Cuppens H, Lin W, Jaspers M, Costes B, Teng H, Vankeerberghen A, Jorissen M, Droogmans G, Reynaert I, Goossens M, Nilius B, Cassiman JJ: Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. The polymorphic (Tg)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation. J Clin Invest 1998;101:487-496.
23. Chen JM, Cutler C, Jacques C, Boeuf G, Denamur E, Lecointre G, Mercier B, Cramb G, Ferec C: A combined analysis of the cystic fibrosis transmembrane conductance regulator: implications for structure and disease models. Mol Biol Evol 2001;18:1771-1788.
24. Norez C, Heda GD, Jensen T, Kogan I, Hughes LK, Auzanneau C, Derand R, Bulteau-Pignoux L, Li C, Ramjeesingh M, Li H, Sheppard DN, Bear CE, Riordan JR, Becq F: Determination of CFTR chloride channel activity and pharmacology using radiotracer flux methods. J Cyst Fibros 2004;3(S2):119-121.
25. Mouchel N, Broackes-Carter F, Harris A: Alternative 5' exons of the CFTR gene show developmental regulation. Hum Mol Genet 2003;12:759-769.
26. Shyu AB, Wilkinson MF, van Hoof A: Messenger RNA regulation: to translate or to degrade. EMBO J 2008;27:471-481.
27. Maquat LE: Nonsense-mediated mRNA decay: splicing, translation and mRNP dynamics. Nat Rev Mol Cell Biol 2004;5:89-99.
28. Kozak M. Pushing the limits of the scanning mechanism for initiation of translation. Gene 2002;299:1-34.
29. Cebotaru L, Vij N, Ciobanu I, Wright J, Flotte T, Guggino WB: Cystic fibrosis transmembrane regulator missing the first four transmembrane segments increases wild type and DeltaF508 processing. J Biol Chem 2008;283:21926-21933.
30. Du K, Sharma M, Lukacs GL: The DeltaF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR. Nat Struct Mol Biol 2005;12:17-25.
31. Lukacs GL, Mohamed A, Kartner N, Chang XB, Riordan JR, Grinstein S: Conformational maturation of CFTR but not its mutant counterpart (delta F508) occurs in the endoplasmic reticulum and requires ATP. EMBO J 1994;13:6076-6086.
32. Ward CL, Kopito RR: Intracellular turnover of cystic fibrosis transmembrane conductance regulator. Inefficient processing and rapid degradation of wild-type and mutant proteins. J Biol Chem 1994;269:25710-25718.
33. Lu Y, Xiong X, Helm A, Kimani K, Bragin A, Skach WR: Co-and posttranslational translocation mechanisms direct cystic fibrosis transmembrane conductance regulator N terminus transmembrane assembly. J Biol Chem 1998;273:568-576.
34. Jurkuvenaite A, Varga K, Nowotarski K, Kirk KL, Sorscher EJ, Li Y, Clancy JP, Bebok Z, Collawn JF: Mutations in the amino terminus of the cystic fibrosis transmembrane conductance regulator enhance endocytosis. J Biol Chem 2006;281:3329-3334.
35. Thelin WR, Chen Y, Gentzsch M, Kreda SM, Sallee JL, Scarlett CO, Borchers CH, Jacobson K, Stutts MJ, Milgram SL: Direct interaction with filamins modulates the stability and plasma membrane expression of CFTR. J Clin Invest 2007;117:364-374.
36. Gene GG, Llobet A, Larriba S, de SD, Martinez I, Escalada A, Solsona C, Casals T, Aran JM: N-terminal CFTR missense variants severely affect the behavior of the CFTR chloride channel. Hum Mutat 2008;29:738-749.
37. Lukaszewicz M, Feuermann M, Jerouville B, Stas A, Boutry M: In vivo evaluation of the context sequence of the translation initiation codon in plants. Plant Sci 2000;154:89-98.
38. Kozak M: Influences of mRNA secondary structure on initiation by eukaryotic ribosomes. Proc Natl Acad Sci U S A 1986;83:2850-2854.
39. Lewandowska M, Costa F, Bischof LM, Williams, SH, Soares MB, Harris A: Multiple mechanisms influence activation of the CFTR gene promoter. Am J Resp Cell Mol Biol. 2009. In press.
40. Ge N, Muise CN, Gong X, Linsdell P: Direct comparison of the functional roles played by different transmembrane regions in the cystic fibrosis transmembrane conductance regulator chloride channel pore. J Biol Chem 2004;279:55283-55289.
41. Sheppard DN, Ostedgaard LS, Rich DP, Welsh MJ: The amino-terminal portion of CFTR forms a regulated Cl-channel. Cell 1994;76:1091-1098